Needham & Company Reiterates Buy on Omeros Corp. (OMER) on Mixed OMS103HP Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Burrill Trims PT on Omeros (OMER) after OMS103HP Results, Keeps Buy Rating
December 28, 2012 8:55 AM ESTBurrill cut its price target on Omeros Corp. (NASDAQ: OMER) from $19 to $16 after OMS103HP did not meet its primary endpoint in patients undergoing arthroscopic partial meniscectomy surgery. However, the firm maintained a Market Outperform as OMS103HP achieved statistically significant reduction of postoperative pain (p=0.0003)... More
Wedbush Says Buy Omeros (OMER) on Weakness from Mixed OMS103HP Phase 3 Results
December 28, 2012 7:21 AM ESTWedbush is telling clients to buy Omeros Corp. (NASDAQ: OMER) on weakness in light of mixed OMS103HP Phase 3 results which has pressured shares 7 percent in extended trading. The firm said the results still warrant continued development and OMS302 is still on track for NDA filing in the 1st-half of 2013.
"Although the primary endpoint of Knee Injury and Osteoarthritis Outcome Score (KOOS) Symptoms subscale trended positively,... More
Omeros (OMER) Said Symptoms Subscale of the KOOS for OMS103HP Did Not Reach Statistical Significance
December 27, 2012 4:04 PM ESTOmeros Corporation (NASDAQ: OMER) reported results from its first pivotal Phase 3 clinical trial evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery. In this multicenter, double-blind, Phase 3 clinical trial comparing OMS103HP to vehicle control in 344 subjects, the pre-specified primary endpoint was the Symptoms Subscale of the Knee Injury and Osteoarthritis Outcome Score (KOOS) a patient-reported measure that is comprised of questions about knee swelling, clicking, catching and stiffness. In addition, pain measured in the early postoperative period was a pre-specified secondary endpoint.
Although the Symptoms Subscale of the KOOS did not reach... More
